2016 American Transplant Congress
Adding an Antimetabolite to a Calcineurin-Inhibitor-Based Immunosuppression Regimen Leads to Improved Native Renal Function After Liver Transplantation.
Surgery, University of Wisconsin, Madison, WI.
Background: Nephrotoxic side effects of calcineurin inhibitors (CNI) have been well established. The addition of anti-metabolites (AM) to CNI-based immunosuppression (IS) regimens has been proposed…2016 American Transplant Congress
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.
Introduction: The UK ONE Study trial investigates the safety and feasibility of regulatory T (Treg) cell therapy in renal transplantation.Materials and Methods: Eleven (9m;2f) living…2016 American Transplant Congress
Influence of Lipid Levels on Cardiovascular Events After Early Conversion from Calcineurin Inhibitor to Everolimus: 24 M Analysis of the ELEVATE Study.
Background: Immunosuppressive therapies are probably the most important cause of hyperlipidemia post-renal transplantation (RTx). Lipid abnormalities represent important biomarkers for cardiovascular (CV) risk. Here, we…2016 American Transplant Congress
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Kidney Transplant Recipients: 3-Months Results from NEVERWOUND Study.
The NEVERWOUND study was designed to evaluate the impact of immediate vs. delayed introduction of everolimus (EVR) on wound healing complications (WHC) and delayed graft…2016 American Transplant Congress
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.
On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.
PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…2016 American Transplant Congress
Learning from Cancer: Using D-Lactate for Therapeutic Immunosuppression.
Accumulation of lactic acid in the tumor microenvironment contributes to local immunosuppressive conditions that weaken anti-tumor immunity. Lactic acid exists as L- and D- optical…2016 American Transplant Congress
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.
Everolimus is associated with long-term benefits, such as preserving renal function and reducing the incidence of infections, malignancies and major cardiovascular events (MACE). The Certic…2016 American Transplant Congress
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.
Northwestern University, Chicago, IL; University of Virginia, Chicago, IL.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Gene Expression Profiling Score and the Risk of Infection in Heart Transplant Recipients.
Purpose: This study assessed the association of gene expression profiling (GEP, AlloMap®) score with infections in heart transplant recipients (HTR). Although a GEP score below…2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…
- « Previous Page
- 1
- …
- 105
- 106
- 107
- 108
- 109
- …
- 138
- Next Page »